News & Events
Read our recent press releases and follow Vascudyne’s newest advancements
Vascudyne Announces First European Clinical Implant for Coronary Artery Bypass
Vascudyne’s acellular tissue engineered vascular conduit used as a coronary artery bypass graft (CABG). The case represents an important milestone in the advancement of tissue-engineered solutions for cardiovascular disease.
Coronary artery disease remains one of the leading causes of morbidity and mortality worldwide, and innovations in graft technology are critical to improving patient outcomes. Vascudyne’s acellular tissue engineered approach is designed to provide a readily available biological solution that supports integration and long-term function.
“This milestone reflects continued progress toward scalable, regenerative therapies that can expand treatment options for patients undergoing bypass surgery,” said Zeeshan Syedain, CEO.
Vascudyne remains committed to advancing next-generation cardiovascular therapies and contributing to the growing field of tissue engineering and regenerative medicine.
Contact Information
Media Contact:
Katherine Lindsay
Vascudyne, Inc.
contact@vascudyne.com
www.vascudyne.com
Forward Looking Statements: This press release contains forward-looking statements regarding future clinical trials and regulatory approvals. Actual results may differ materially from those projected.
Address
Social Media
These are investigational uses that have not been approved by any health authority. Safety and efficacy have not been established and there is no guarantee that pipeline products or investigational uses will receive approval from health authorities.
Copyright 2025 | Vascudyne, Inc.
